US5079262A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
Assignee: Queen's University
•
Filing: 1989-07-28
•
Granted: 1992-01-07
•
Expires: 2009-07-28
Abstract
Abstract A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin, conjunctives, respiratory, digestive and vaginal mucosa; endometrium and urothelium in which 5-aminolevulinic acid is administered to the patient in an amount sufficient to induce synthesis of protoporphyrin IX in the leisons, followed by exposure of the treated lesion to a photoactivating light in the range 350-640 nm.
Inventors
- 👤 James C. Kennedy
- 👤 Roy H. Pottier
- 👤 Robert L. Reid
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/33; A61K31/555; A61K41/00; A61K41/0057; A61K41/0061; A61P; A61P35/00; A61P43/00
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
72 words
A method for treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium; and urothelium which are sensitive to protoporphyrin IX in a patient in need thereof comprising administering to said patient an effective amount of 5-aminolevulinic acid so as to induce synthesis of protoporphyrin IX in said lesions, and exposing said lesions to light within the photoactivating action spectrum of said photoporphyrin IX.
Claim 2
Independent Claim
72 words
A method for treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium; and urothelium which are sensitive to protoporphyrin IX in a patient in need thereof comprising administering to said patient an effective amount of 5-aminolevulinic acid so as to induce synthesis of protoporphyrin IX in said lesions, and exposing said lesions to light within the photoactivating action spectrum of said photoporphyrin IX.
Claim 3
Dependent Claim
19 words
A method as claimed in claim 1 wherein said malignant lesions are selected from basal, baso-squamous and squamous carcinomas.
Claim 4
Dependent Claim
18 words
A method as claimed in claim 1 wherein said non-malignant lesions are selected from psoriasis and genital warts.
Claim 5
Dependent Claim
17 words
A method as claimed in claim 1 wherein said photoactivating light is in the range 350-640 nm.
Claim 6
Dependent Claim
14 words
A method as claimed in claim 1 wherein said 5-aminolevulinic acid is administered parenterally.
Claim 7
Dependent Claim
14 words
A method as claimed in claim 1 wherein said 5-aminolevulinic acid is administered topically.
Claim 8
Dependent Claim
14 words
A method as claimed in claim 1 wherein said 5-aminolevulinic acid is administered orally.
References Cited (Backward Citations)
US3934369A
Cited
US3973129A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-01-06 | 1995-07-08 | 1996-01-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-01-06 | 1999-07-08 | 2000-01-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-01-06 | 2003-07-08 | 2004-01-07 | $7700.00 | Window Closed / Lapsed |